Her-2 oncogene amplification, chromosome 17 and DNA ploidy status in synovial sarcoma

Z. Sápi, Zsuzsa Pápai, Anett Hruska, I. Antal, Miklós Bodó, Zsolt Orosz

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The treatment options for synovial sarcoma (SS) are very limited, though this type of sarcoma seems to be more heterogeneous than it has been traditionally considered. The present study investigates the Her-2 oncogene status of 20 cases of SS, to determine whether Her-2 amplification can be considered as a prognostic factor. Her-2 oncogene amplification was determined on smears (frozen material was used from our tumor bank in each case), using fluorescence in situ hybridization technique (dual color FISH with centromeric probe for chromosome 17 and specific probe for Her-2 oncogene). Moreover, protein expression was assessed by immunohistochemistry, and DNA ploidy status was measured using image analysis. We had 5 biphasic and 15 monophasic SSs, patients′ age ranged from 13 to 68 years (mean, 39.8 years). Tumor size was larger than 5 cm in each case. Follow-up time ranged from 6 to 78 months (mean, 38.5 months). For statistical analysis the chi-square test was used. Her-2 oncogene amplification was found in three cases (15.0%) of 20 SSs. These cases proved to be 2+ positive by immunohistochemistry, but massive amplification, characteristic of a subset of breast carcinomas, was not observed. Her-2 oncogene amplification was significantly associated with a lower risk of developing metastasis (P

Original languageEnglish
Pages (from-to)133-138
Number of pages6
JournalPathology and Oncology Research
Volume11
Issue number3
Publication statusPublished - 2005

Fingerprint

Synovial Sarcoma
Chromosomes, Human, Pair 17
Ploidies
Oncogenes
DNA
Immunohistochemistry
Chi-Square Distribution
Fluorescence In Situ Hybridization
Sarcoma
Neoplasms
Color
Breast Neoplasms
Neoplasm Metastasis
Proteins

Keywords

  • DNA ploidy
  • FISH
  • Her-2 oncogene
  • Immunohistochemistry
  • Prognostic factor
  • Synovial sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Her-2 oncogene amplification, chromosome 17 and DNA ploidy status in synovial sarcoma. / Sápi, Z.; Pápai, Zsuzsa; Hruska, Anett; Antal, I.; Bodó, Miklós; Orosz, Zsolt.

In: Pathology and Oncology Research, Vol. 11, No. 3, 2005, p. 133-138.

Research output: Contribution to journalArticle

Sápi, Z. ; Pápai, Zsuzsa ; Hruska, Anett ; Antal, I. ; Bodó, Miklós ; Orosz, Zsolt. / Her-2 oncogene amplification, chromosome 17 and DNA ploidy status in synovial sarcoma. In: Pathology and Oncology Research. 2005 ; Vol. 11, No. 3. pp. 133-138.
@article{ad354935e290444e96a8591060505b8d,
title = "Her-2 oncogene amplification, chromosome 17 and DNA ploidy status in synovial sarcoma",
abstract = "The treatment options for synovial sarcoma (SS) are very limited, though this type of sarcoma seems to be more heterogeneous than it has been traditionally considered. The present study investigates the Her-2 oncogene status of 20 cases of SS, to determine whether Her-2 amplification can be considered as a prognostic factor. Her-2 oncogene amplification was determined on smears (frozen material was used from our tumor bank in each case), using fluorescence in situ hybridization technique (dual color FISH with centromeric probe for chromosome 17 and specific probe for Her-2 oncogene). Moreover, protein expression was assessed by immunohistochemistry, and DNA ploidy status was measured using image analysis. We had 5 biphasic and 15 monophasic SSs, patients′ age ranged from 13 to 68 years (mean, 39.8 years). Tumor size was larger than 5 cm in each case. Follow-up time ranged from 6 to 78 months (mean, 38.5 months). For statistical analysis the chi-square test was used. Her-2 oncogene amplification was found in three cases (15.0{\%}) of 20 SSs. These cases proved to be 2+ positive by immunohistochemistry, but massive amplification, characteristic of a subset of breast carcinomas, was not observed. Her-2 oncogene amplification was significantly associated with a lower risk of developing metastasis (P",
keywords = "DNA ploidy, FISH, Her-2 oncogene, Immunohistochemistry, Prognostic factor, Synovial sarcoma",
author = "Z. S{\'a}pi and Zsuzsa P{\'a}pai and Anett Hruska and I. Antal and Mikl{\'o}s Bod{\'o} and Zsolt Orosz",
year = "2005",
language = "English",
volume = "11",
pages = "133--138",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Her-2 oncogene amplification, chromosome 17 and DNA ploidy status in synovial sarcoma

AU - Sápi, Z.

AU - Pápai, Zsuzsa

AU - Hruska, Anett

AU - Antal, I.

AU - Bodó, Miklós

AU - Orosz, Zsolt

PY - 2005

Y1 - 2005

N2 - The treatment options for synovial sarcoma (SS) are very limited, though this type of sarcoma seems to be more heterogeneous than it has been traditionally considered. The present study investigates the Her-2 oncogene status of 20 cases of SS, to determine whether Her-2 amplification can be considered as a prognostic factor. Her-2 oncogene amplification was determined on smears (frozen material was used from our tumor bank in each case), using fluorescence in situ hybridization technique (dual color FISH with centromeric probe for chromosome 17 and specific probe for Her-2 oncogene). Moreover, protein expression was assessed by immunohistochemistry, and DNA ploidy status was measured using image analysis. We had 5 biphasic and 15 monophasic SSs, patients′ age ranged from 13 to 68 years (mean, 39.8 years). Tumor size was larger than 5 cm in each case. Follow-up time ranged from 6 to 78 months (mean, 38.5 months). For statistical analysis the chi-square test was used. Her-2 oncogene amplification was found in three cases (15.0%) of 20 SSs. These cases proved to be 2+ positive by immunohistochemistry, but massive amplification, characteristic of a subset of breast carcinomas, was not observed. Her-2 oncogene amplification was significantly associated with a lower risk of developing metastasis (P

AB - The treatment options for synovial sarcoma (SS) are very limited, though this type of sarcoma seems to be more heterogeneous than it has been traditionally considered. The present study investigates the Her-2 oncogene status of 20 cases of SS, to determine whether Her-2 amplification can be considered as a prognostic factor. Her-2 oncogene amplification was determined on smears (frozen material was used from our tumor bank in each case), using fluorescence in situ hybridization technique (dual color FISH with centromeric probe for chromosome 17 and specific probe for Her-2 oncogene). Moreover, protein expression was assessed by immunohistochemistry, and DNA ploidy status was measured using image analysis. We had 5 biphasic and 15 monophasic SSs, patients′ age ranged from 13 to 68 years (mean, 39.8 years). Tumor size was larger than 5 cm in each case. Follow-up time ranged from 6 to 78 months (mean, 38.5 months). For statistical analysis the chi-square test was used. Her-2 oncogene amplification was found in three cases (15.0%) of 20 SSs. These cases proved to be 2+ positive by immunohistochemistry, but massive amplification, characteristic of a subset of breast carcinomas, was not observed. Her-2 oncogene amplification was significantly associated with a lower risk of developing metastasis (P

KW - DNA ploidy

KW - FISH

KW - Her-2 oncogene

KW - Immunohistochemistry

KW - Prognostic factor

KW - Synovial sarcoma

UR - http://www.scopus.com/inward/record.url?scp=27644516035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644516035&partnerID=8YFLogxK

M3 - Article

C2 - 16195766

AN - SCOPUS:27644516035

VL - 11

SP - 133

EP - 138

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 3

ER -